Parallel Advisors, LLC Mirati Therapeutics, Inc. Transaction History

Parallel Advisors, LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$41.99 - $62.38 $91,622 - $136,113	-2,182 Reduced 94.62%	124 $7,000
Q3 2023 May 20, 2024	BUY	$27.8 - $45.35 $19,849 - $32,379	714 Added 44.85%	2,306 $100,000
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $19,849 - $32,379	714 Added 44.85%	2,306 $100,000
Q2 2023 May 20, 2024	BUY	$36.13 - $49.49 $6,467 - $8,858	179 Added 12.67%	1,592 $57,000
Q2 2023 Aug 04, 2023	BUY	$36.13 - $49.49 $6,467 - $8,858	179 Added 12.67%	1,592 $57,000
Q1 2023 May 20, 2024	BUY	$36.54 - $54.26 $51,631 - $76,669	1,413 New	1,413 $52,000
Q1 2023 Apr 25, 2023	SELL	$36.54 - $54.26 $9,390 - $13,944	-257 Reduced 15.39%	1,413 $52,000
Q4 2022 Feb 03, 2023	BUY	$41.27 - $98.62 $22,533 - $53,846	546 Added 48.58%	1,670 $75,000
Q3 2022 Nov 10, 2022	BUY	$59.5 - $86.7 $8,984 - $13,091	151 Added 15.52%	1,124 $79,000
Q2 2022 Aug 01, 2022	BUY	$39.16 - $88.71 $23,574 - $53,403	602 Added 162.26%	973 $65,000
Q1 2022 Apr 28, 2022	BUY	$75.82 - $150.97 $21,229 - $42,271	280 Added 307.69%	371 $31,000
Q4 2021 Jan 20, 2022	BUY	$132.01 - $190.29 $8,580 - $12,368	65 Added 250.0%	91 $13,000
Q3 2021 Nov 02, 2021	BUY	$132.13 - $177.45 $2,774 - $3,726	21 Added 420.0%	26 $5,000
Q2 2021 Aug 06, 2021	SELL	$144.0 - $179.73 $2,592 - $3,235	-18 Reduced 78.26%	5 $1,000
Q1 2021 Apr 23, 2021	BUY	$158.92 - $221.61 $635 - $886	4 Added 21.05%	23 $4,000
Q4 2020 Feb 02, 2021	BUY	$162.05 - $240.27 $2,106 - $3,123	13 Added 216.67%	19 $4,000
Q3 2020 Oct 27, 2020	BUY	$113.26 - $167.27 $679 - $1,003	6 New	6 $1,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.